What the market must start to realize, IMO very humble opinion :) is:
- anti-PS targeting is not just done by the next MAB with single action, that is 'CAP' something to avoid binding. Bavituximab is that more sophisticated Global/Upstream/Systemic MAB and is extremely safe compared to everything out there.
- and PS is EVERYWHERE hence the potential applications for this drug are unseen and ranges over many fields of medicine, not just oncology or a single leg of oncology (radio, chemo, immuno).
- PPHM has IP, pipelines and award winning 'single use & forward only' manufacturing facilities for biological substances up and running and has a poison pill to keep it from being hostile acquired for breadcrumbs while having cash on the bank and stock funding programs readily available.